{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:04Z","timestamp":1787430304615,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Diabetes & Endocrinology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/s2213-8587(26)00160-9","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:03:17Z","timestamp":1787367797000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial"],"prefix":"10.1016","author":[{"given":"Stanley H","family":"Hsia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana K","family":"Billings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie K","family":"Weideman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai San","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia Ferreira Galvao","family":"De Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2213-8587(26)00160-9_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2213-8587(25)00197-4","article-title":"Beyond a singular focus on GLP-1: why we need a new nomenclature now","volume":"13","author":"Muskiet","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00160-9_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.peptides.2018.04.008","article-title":"Oxyntomodulin analogue increases energy expenditure via the glucagon receptor","volume":"104","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/S2213-8587(26)00160-9_bib3","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.cmet.2022.10.001","article-title":"The past, present, and future physiology and pharmacology of glucagon","volume":"34","author":"Capozzi","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/S2213-8587(26)00160-9_bib4","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1111\/dom.15693","article-title":"Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity","volume":"26","author":"Winther","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S2213-8587(26)00160-9_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S2213-8587(26)00160-9_bib6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/S2213-8587(26)00160-9_bib7","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/S2213-8587(26)00160-9_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/S2213-8587(26)00160-9_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/oby.24184","article-title":"Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE\u2122-1 and -2)","volume":"33","author":"Wharton","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00160-9_bib10","article-title":"306-OR: Mazdutide vs placebo as monotherapy in patients with type 2 diabetes (DREAMS-1)","volume":"74","author":"Zhu","year":"2025","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00160-9_bib11","article-title":"682-P: novel dual glucagon and glucagon-like peptide-1 receptor agonist LY3305677 improves glucose control, reduces body weight, and increases energy expenditure in mice","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/S2213-8587(26)00160-9_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/S2213-8587(26)00160-9_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/S2213-8587(26)00160-9_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-44067-4","article-title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/S2213-8587(26)00160-9_bib15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib16","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-025-02249-y","article-title":"Mazdutide: first approval","volume":"85","author":"Shirley","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/S2213-8587(26)00160-9_bib17","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1111\/dom.70040","article-title":"Mazdutide reduces body weight in adults with overweight or obesity: a high-dose phase 1 trial","volume":"27","author":"Bhattachar","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S2213-8587(26)00160-9_bib18","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1002\/mrm.28360","article-title":"Reproducibility and repeatability of MRI-based body composition analysis","volume":"84","author":"Borga","year":"2020","journal-title":"Magn Reson Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/19466315.2022.2025893","article-title":"Efficient estimation of the efficacy and safety endpoints for clinical trials with preplanned dose titrations","volume":"15","author":"Qu","year":"2023","journal-title":"Stat Biopharm Res"},{"key":"10.1016\/S2213-8587(26)00160-9_bib20","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/S2213-8587(26)00160-9_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib22","article-title":"Fat infiltration in skeletal muscle: influential triggers and regulatory mechanism","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"10.1016\/S2213-8587(26)00160-9_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00160-9_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S2213-8587(26)00160-9_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/S2213-8587(26)00160-9_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.868037","article-title":"Is glucagon receptor activation the thermogenic solution for treating obesity?","volume":"13","author":"Concei\u00e7\u00e3o-Furber","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/S2213-8587(26)00160-9_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1152\/physrev.00028.2023","article-title":"Hepatic glucagon action: beyond glucose mobilization","volume":"104","author":"Kajani","year":"2024","journal-title":"Physiol Rev"},{"key":"10.1016\/S2213-8587(26)00160-9_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.18383\/j.tom.2019.00018","article-title":"Quantification of human central adipose tissue depots: an anatomically matched comparison between DXA and MRI","volume":"5","author":"Crabtree","year":"2019","journal-title":"Tomography"},{"key":"10.1016\/S2213-8587(26)00160-9_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adl4909","article-title":"Obesity reshapes regulatory T cells in the visceral adipose tissue by disrupting cellular cholesterol homeostasis","volume":"10","author":"Elkins","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/S2213-8587(26)00160-9_bib32","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"suppl 1","key":"10.1016\/S2213-8587(26)00160-9_bib33","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J Endocr Soc"}],"container-title":["The Lancet Diabetes & Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213858726001609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:05:33Z","timestamp":1787429133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858726001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S2213858726001609"],"URL":"https:\/\/doi.org\/10.1016\/s2213-8587(26)00160-9","relation":{},"ISSN":["2213-8587"],"issn-type":[{"value":"2213-8587","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Diabetes & Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00160-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2213-8587(26)00187-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}